The moment clinical AI expands, this is the infrastructure layer it needs. Two loops. One rail.
Amazon's launch of a Health AI assistant on its consumer platform confirms that AI will mediate patient decisions at scale, routing millions of people through AI-generated health guidance before they ever reach a clinic.
This creates a structural shift. As AI surfaces recommendations across the care journey, the downstream moment — the clinical recommendation itself — becomes newly visible, newly capturable, and newly valuable. Not just as a transaction. As a signal.
The infrastructure layer that captures both doesn't exist yet.
Revytal is building it.
Amazon, Microsoft, and OpenAI are investing in health navigation, virtual care, and clinical documentation. They are not capturing OTC and product intent from outpatient providers. They are not building compliant commerce infrastructure for physical therapy clinics, primary care, dermatology, podiatry, urgent care, orthopedic practices, or sports medicine groups. And none of them are building the evidence layer that sits on top of it.
The category is being validated from above. The ground-level infrastructure and the insight layer it enables remain unbuilt. That gap is Revytal's entry point and its moat.
Providers recommend braces, orthotics, supplements, OTC products, topicals, and recovery equipment in every session. The recommendation is trusted. The patient acts on it. The purchase happens somewhere else. The clinic sees none of the revenue and none of the outcome data.
There is no compliant, automated mechanism for capturing that demand. No product built for the outpatient workflow. No rail between the clinical moment and the transaction. No system surfacing what the pattern of recommendations reveals over time.
Revytal gives providers a new revenue stream and a new evidence layer without adding a single step to the clinical workflow.
The behavior exists. The intent is already there. The only missing piece is infrastructure that makes the clinic the starting point rather than Amazon, and that routes the outcome data back to the provider who made the call.
HSA-eligible checkout and clinical-grade SKUs reinforce the trust that already exists. Revytal doesn't create new behavior. It captures existing behavior and closes the loop on it.
The tools that have tried to enter outpatient workflows have failed on friction: HIPAA compliance burdens, EHR dependency, six-month implementation cycles. Revytal is architecturally different. No patient data is stored. No EHR touchpoint is required. A clinic can run its first live order the same day it activates.
The same architecture that makes commerce frictionless makes evidence aggregation compliant by design. Revytal captures signal at the population level, not the patient level, which keeps the system outside PHI constraints while still generating meaningful clinical insight over time.
In a category where friction is the primary adoption barrier, zero friction is a structural advantage.
Amazon commoditizes product recommendations and erodes supplier margin. Suppliers selling through outpatient clinics get something Amazon cannot offer: clinical endorsement, patient trust, and a direct fulfillment relationship grounded in a care context.
Over time, Revytal gives suppliers something even more valuable: aggregated signal on which products clinicians actually reach for, and which correlate with better patient outcomes. That is a dataset no retailer can build. It makes Revytal a strategic partner to suppliers, not just a distribution channel.
Revytal gives suppliers a defensible distribution channel through the most credible sales environment that exists. The provider relationship. That channel doesn't exist today.
As documentation, scheduling, and billing move toward invisible automation, the clinical encounter becomes a structured signal. Recommendations that were previously verbal, untracked, and uncaptured become discrete, actionable events.
That structural shift creates a new category: Clinical Commerce Infrastructure, the rail between provider intent and patient action. But the category has a second layer that most people haven't named yet: the evidence loop that emerges when you aggregate those signals at scale.
The commerce layer closes the revenue gap. The evidence layer raises the floor of clinical decision-making.
The company that builds both names the category and sets the terms for everything that follows.
This is not a market identified through research. It is a problem lived from the inside, watching revenue leak out of the system on every patient visit, watching clinicians make recommendations with no feedback on what happened next, and understanding the exact constraints that make clinical workflows resistant to new tools.
Infrastructure companies in healthcare require founder-market fit that goes beyond domain knowledge. It requires having been the person who needed both the revenue rail and the evidence loop and found nothing there. That is the founder insight Revytal is built on.
The clinical recommendation is the most trusted commercial signal in healthcare. It has never been captured. The infrastructure to capture it has never been built. And the evidence layer that turns captured signals into clinical insight has never existed.
Ambient AI is making the recommendation moment visible for the first time. Big Tech is validating AI-mediated healthcare at scale. Outpatient clinics are actively looking for non-insurance revenue and better-supported clinical decisions. Suppliers need a non-Amazon channel with outcome data attached. Patients already act on what providers recommend.
Two loops. One rail. The category will be defined by whoever builds both first.
Revytal is building it now.